CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of thyroid cancer and neuroendocrine tumors.
  
  LEARNING OBJECTIVES

  • Evaluate the efficacy and safety of multitargeted tyrosine kinase inhibitors for advanced thyroid cancer, and discern how these agents can be optimally employed in first- and later-line care.
  • Recognize the spectrum and prevalence of potentially targetable genomic alterations in patients with thyroid cancer, and discuss the means by which these alterations contribute to tumor growth and proliferation.
  • Analyze available safety and efficacy results with novel RET inhibitors for RET-driven thyroid cancer, and appropriately integrate these agents into current treatment algorithms.
  • Consider the clinical relevance of NTRK gene fusions in thyroid cancer, and appreciate available clinical research evidence with and FDA endorsements for TRK inhibitors in this subgroup of patients.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for thyroid cancer, and counsel appropriate patients about availability and participation.
  • Appreciate the variability in clinical presentation, pace of growth and prognosis of different anatomical subtypes of neuroendocrine tumors (NETs) and evaluate how these and other patient- and disease-related factors affect the selection and sequencing of systemic treatment for unresectable or metastatic forms of this disease.
  • Review published research findings supporting the use of somatostatin analogs in patients with advanced NETs to optimally incorporate these agents into current clinical management algorithms.
  • Understand the incidence, clinical manifestations and optimal management of carcinoid syndrome associated with NETs, and use this information to appropriately employ currently approved therapies for patients experiencing inadequately controlled carcinoid syndrome diarrhea.
  • Appraise the documented prevalence of von Hippel-Lindau syndrome-associated NETs, and develop strategies to care for patients with this unique manifestation of the disease.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty and moderator reported relevant financial relationships with ineligible entities:
  
  Jonathan Strosberg, MD
  Professor, Dept of GI Oncology
  Moffitt Cancer Center
  Tampa, Florida
  
  Consulting Agreement: Novartis; Contracted Research: Novartis, Orano Med, RadioMedix Inc, RayzeBio; Speakers Bureau: Ipsen Biopharmaceuticals Inc, TerSera Therapeutics LLC.
  
  Lori J Wirth, MD
  The Elizabeth and Michael Ruane Chair of Endocrine Oncology Associate Professor
  Harvard Medical School
  Medical Director, Head and Neck Oncology
  Massachusetts General Hospital
  Boston, Massachusetts
  
  Advisory Committee: Eisai Inc; Consulting Agreements: Eisai Inc, Exelixis Inc, Lilly, Merck.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GSK, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Blueprint Medicines and Genentech, a member of the Roche Group, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, and TerSera Pharmaceuticals LLC.
  
  Release date: February 2023
  Expiration date: February 2024